| Literature DB >> 31569646 |
René López1,2, Rodrigo Pérez-Araos3,4, Álvaro Salazar5, Ana L Ulloa6, Cecilia Vial7, Pablo A Vial8,9,10, Jerónimo Graf11,12.
Abstract
Hantavirus cardiopulmonary syndrome (HCPS) is characterized by capillary leak, pulmonary edema (PE), and shock, which leads to death in up to 40% of patients. Treatment is supportive, including mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO). Hemodynamic monitoring is critical to titrate therapy and to decide ECMO support. Transpulmonary thermodilution (TPTD) provides hemodynamic and PE data that have not been systematically used to understand HCPS pathophysiology. We identified 11 HCPS patients monitored with TPTD: eight on MV, three required ECMO. We analyzed 133 measurements to describe the hemodynamic pattern and its association with PE. The main findings were reduced stroke volume, global ejection fraction (GEF), and preload parameters associated with increased extravascular lung water and pulmonary vascular permeability compatible with hypovolemia, myocardial dysfunction, and increased permeability PE. Lung water correlated positively with heart rate (HR, r = 0.20) and negatively with mean arterial pressure (r = -0.27) and GEF (r = -0.36), suggesting that PE is linked to hemodynamic impairment. Pulmonary vascular permeability correlated positively with HR (r = 0.31) and negatively with cardiac index (r = -0.49), end-diastolic volume (r = -0.48), and GEF (r = -0.40), suggesting that capillary leak contributes to hypovolemia and systolic dysfunction. In conclusion, TPTD data suggest that in HCPS patients, increased permeability leads to PE, hypovolemia, and circulatory impairment.Entities:
Keywords: Andes virus; Hantavirus cardiopulmonary syndrome; Hantavirus pulmonary syndrome; pulmonary edema; transpulmonary thermodilution
Year: 2019 PMID: 31569646 PMCID: PMC6832621 DOI: 10.3390/v11100900
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Schematic representation of intrathoracic volumes assessment by transpulmonary thermodilution (TPTD). The technique is based on central venous injection of cold saline and its detection close to the aorta usually via a femoral artery catheter. The temperature–time (thermodilution) curve generated after passage of the indicator through the central circulation and the lungs is illustrated on the right side of the site of detection. The three main volumes computed are depicted on the right side of the thermodilution curve. Global end-diastolic volume (GEDV) consists of left and right, atrial and ventricular end-diastolic volumes (top). Intrathoracic blood volume (ITBV) is the GEDV plus the pulmonary blood volume (middle). GEDV and ITBV are volumetric preload parameters. Extravascular lung water (EVLW), a pulmonary edema quantification index, is the volume of fluid in the pulmonary interstitium and alveolar spaces accessible to thermal diffusion from the pulmonary capillaries (bottom). Figure modified from Non-Communicable Diseases, Emergency Care and Mental Health module of the HEAT Programme, Module: 1. Cardiovascular Diseases, 1.2 Anatomy and physiology of the heart. An OpenLearn Create chunk used/reworked by permission of The Open University © (2011), (https://www.open.edu/openlearncreate/mod/oucontent/view.php?id=287&printable=1&extra=thumbnailfigure_idm4070912).
Demographic and clinical, characteristics of patients with hantavirus cardiopulmonary syndrome (HCPS) monitored with transpulmonary thermodilution (TPTD). Sequential organ failure assessment (SOFA), acute physiology and chronic health evaluation (APACHE II), veno-arterial extracorporeal membrane oxygenation (VA-ECMO), intensive care unit (ICU), length of stay (LOS).
| Characteristic | Value |
|---|---|
| Male, N (%) | 7 (64) |
| Age, years, median (range) | 29 (15–59) |
| SOFA score, points, median (range) | 9 (4–14) |
| APACHE II score, points, median (range) | 10 (5–30) |
| Invasive mechanical ventilation, N (%) | 8 (73) |
| Inotropic drugs, N (%) | 8 (73) |
| VA-ECMO, N (%) | 3 (27) |
| ICU-LOS, days, median (range) | 6 (4–18) |
| Hospital-LOS, days, median (range) | 12 (4–87) |
Descriptive analysis of transpulmonary thermodilution (TPTD) variables. Data are expressed as median and interquartile range (IQR). Reference values are given for each variable. dPmax is the maximal change of arterial pressure per second.
| Transpulmonary Thermodilution Variables | Median (IQR) | Reference Range |
|---|---|---|
|
| ||
| Heart rate, beats/min | 99 (90–109) | 60–100 |
| Mean arterial pressure, mmHg | 82 (75–89) | 70–90 |
| Central venous pressure, mmHg | 8 (4–11) | 6–12 |
| Cardiac index, L/min/m2 | 3.1 (2.5–3.8) | 3.0–5.0 |
| Stroke index, mL/m2 | 34 (26–41) | 40–60 |
| Systemic vascular resistance index, dyn·sec·cm−5·m−2 | 1880 (1546–2364) | 1700–2400 |
|
| ||
| Global ejection fraction, % | 24 (21–27) | 25–35 |
| Cardiac function index, 1/min | 5.6 (5.0–6.3) | 4.5–6.5 |
| dPmax, mmHg/s | 950 (762–1094) | 900–1200 |
|
| ||
| Intrathoracic blood volume index, mL/m2 | 667 (553–790) | 850–1000 |
| Global end diastolic volume index, mL/m2 | 538 (442–635) | 680–800 |
|
| ||
| Stroke volume variation, % | 13 (8–17) | ≤10 |
|
| ||
| Extravascular lung water index, mL/Kg | 13.1 (10.2–17.3) | 3.0–7.0 |
| Pulmonary vascular permeability index, dimensionless | 3.2 (2.7–4.7) | 1.0–3.0 |
Pearson correlations between pulmonary edema (PE) and hemodynamic variables. PE variables are the extravascular lung water index (EVLWi) and pulmonary vascular permeability index (PVPI). Hemodynamic variables are categorized as classic hemodynamic, myocardial contractility, cardiac preload, and fluid responsive prediction variables. dPmax is the maximal change of arterial pressure per second.
| Transpulmonary Thermodilution Variables | EVLWi | PVPI | ||
|---|---|---|---|---|
|
| ||||
| Heart rate, beats/min | 0.20 | 0.02 | 0.31 | <0.01 |
| Mean arterial pressure, mmHg | −0.27 | <0.01 | −0.10 | 0.26 |
| Central venous pressure, mmHg | 0.23 | 0.01 | 0.26 | <0.01 |
| Cardiac index, L/min/m2 | 0.02 | 0.79 | −0.49 | <0.01 |
| Stroke index, mL/m2 | 0.06 | 0.51 | −0.12 | 0.17 |
| Systemic vascular resistance index, dyn·sec·cm−5·m2 | −0.18 | 0.04 | 0.38 | <0.01 |
|
| ||||
| Global ejection fraction, % | −0.36 | <0.01 | −0.40 | <0.01 |
| Cardiac function index, 1/min | −0.25 | <0.01 | −0.20 | 0.02 |
| dPmax, mmHg/s | 0.12 | 0.18 | 0.16 | 0.08 |
|
| ||||
| Intrathoracic blood volume index, mL/m2 | 0.21 | 0.01 | −0.48 | <0.01 |
| Global end diastolic volume index, mL/m2 | 0.21 | 0.01 | −0.48 | <0.01 |
|
| ||||
| Stroke volume variation, % | 0.10 | 0.28 | 0.22 | 0.01 |
Dichotomic analysis of transpulmonary thermodilution (TPTD) measurements according to extravascular lung water index (EVLWi) with a threshold of 15 mL/Kg. dPmax is the maximal change of arterial pressure per second. Values are mean with standard deviation (SD) in parenthesis. Comparisons were made using the t-test.
| Hemodynamic Variables | EVLWi < 15 mL/kg | EVLWi ≥ 15 mL/kg | |
|---|---|---|---|
|
| |||
| Heart rate, beats/min | 96 (18) | 103 (14) | 0.02 |
| Mean arterial pressure, mmHg | 84 (10) | 79 (9) | <0.01 |
| Central venous pressure, mmHg | 6 (4) | 10 (5) | <0.01 |
| Cardiac index, L/min/m2 | 3.2 (0.9) | 3.1 (0.9) | 0.74 |
| Stroke index, mL/m2 | 34 (9) | 35 (30) | 0.75 |
| Systemic vascular resistance index, dyn·sec·cm−5·m2 | 2093 (702) | 1915 (620) | 0.15 |
|
| |||
| Global ejection fraction, % | 25 (4) | 22 (5) | <0.01 |
| Cardiac function index, 1/min | 5.9 (1.1) | 5.4 (0.9) | 0.01 |
| dPmax, mmHg/s | 925 (223) | 1007 (304) | 0.12 |
|
| |||
| Intrathoracic blood volume index, mL/m2 | 680 (172) | 735 (222) | 0.12 |
| Global end diastolic volume index, mL/m2 | 546 (138) | 588 (177) | 0.14 |
|
| |||
| Stroke volume variation, % | 13 (6) | 14 (7) | 0.68 |
|
| |||
| Extravascular lung water index, mL/Kg | 11.1 (2.2) | 20.0 (4.3) | <0.01 |
| Pulmonary vascular permeability index, dimensionless | 3.1 (0.9) | 5.1 (1.7) | <0.01 |
Figure 2Time course of heart rate (HR), systolic index (SI), extravascular lung water index (EVLWi) and pulmonary vascular permeability index (PVPI) in a representative patient that required veno-arterial extracorporeal membrane oxygenation (VA-ECMO) (Patient 2) and in a representative patient that did not require VA-ECMO support (Patient 4).